Car T-Cell Therapy

Adoptive cellular therapies such as chimeric antigen receptor T-cell therapy have transformed the landscape of care for patients with relapsed or refractory hematologic malignancies.

Sikander Ailawadhi, MD, discusses the importance of addressing health care disparities in multiple myeloma.

Sikander Ailawadhi, MD, discusses how awareness of multiple myeloma can improve among patients, providers and the general public.

Sikander Ailawadhi, MD, discusses what’s new in the multiple myeloma space.

More evidence has emerged that T-cell lymphoma following chimeric antigen receptor T-cell therapy is both rare and not necessarily caused by the treatment.

In this video, Tycel Phillips, MD, discusses high-risk subtypes of DLBCL and how to manage these cases.

SCOTTSDALE, Ariz. — Chimeric antigen receptor T-cell therapy had “unprecedented” and “astonishing” results in lupus, but whether it will truly revolutionize rheumatology care remains to be seen, according to a speaker.

Allogeneic hematopoietic stem cell transplantation after CD19 chimeric antigen receptor T-cell therapy is thought to improve leukemia-free survival.